Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/1999
10/14/1999WO1999051252A1 Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
10/14/1999WO1999051246A1 Antitumor agents
10/14/1999WO1999051245A1 Non-peptide bradykinin receptor antagonists for use in treating ophthalmic diseases and disorders
10/14/1999WO1999051244A1 Use of phospholipids for the manufacture of a medicament for the prevention of adhesions
10/14/1999WO1999051243A1 THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY
10/14/1999WO1999051242A1 Medicinal compositions for treating edema
10/14/1999WO1999051241A1 Calcilytic compounds and method of use
10/14/1999WO1999051240A1 Acylbenzoxazines for enhancing synaptic response(s)
10/14/1999WO1999051239A1 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
10/14/1999WO1999051238A1 Semi-synthetic ecteinascidins
10/14/1999WO1999051237A1 Oral liquid antidepressant solution
10/14/1999WO1999051236A1 Methods for inhibiting mrp1
10/14/1999WO1999051235A1 Non-peptide bradykinin receptor antagonists for use in controlling intraocular pressure and treating glaucoma
10/14/1999WO1999051234A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051233A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051232A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051231A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051230A1 Method for stabilizing pharmaceutical compositions by special use of an antioxidant
10/14/1999WO1999051229A1 Treatment of panic attacks
10/14/1999WO1999051228A1 Methods for inhibiting mrp1
10/14/1999WO1999051227A1 Methods for inhibiting mrp1
10/14/1999WO1999051226A1 Use of aminothiazole derivatives for preparing medicines for treating diseases causing demyelinization
10/14/1999WO1999051225A1 Antidiabetic agents
10/14/1999WO1999051224A1 Indolyl-3-glyoxylic acid derivatives with antitumoral activity
10/14/1999WO1999051223A1 Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
10/14/1999WO1999051220A1 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin
10/14/1999WO1999051219A1 Pleuromutilin derivatives for treating nasopharynx infection
10/14/1999WO1999051218A1 Biocidal compositions comprising lactic acid and at least one other acid selected from formic acid, acetic acid and propionic acid
10/14/1999WO1999051217A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
10/14/1999WO1999051216A2 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
10/14/1999WO1999051215A2 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
10/14/1999WO1999051214A2 Progestogen-only contraceptive kit
10/14/1999WO1999051213A2 The use of polyamines in the treatment of dermatological symptoms
10/14/1999WO1999051212A2 Device for the transdermal delivery of diclofenac
10/14/1999WO1999051206A1 Cationic lipid formulation delivering nucleic acid to peritoneal tumors
10/14/1999WO1999051205A1 Aerosol composition
10/14/1999WO1999051203A1 Maximizing effectiveness of substances used to improve health and well being
10/14/1999WO1999051202A2 Quinolone containing liposomes and their use as antibacterial agents
10/14/1999WO1999051200A1 Cosmetic or pharmaceutical agents containing ribonucleic or desoxyribonucleic acids
10/14/1999WO1999051198A1 Dermatological formulations and methods
10/14/1999WO1999051097A1 Compositions containing a combination of a creatine compound and a second agent
10/14/1999WO1999051096A1 Pulmonary and nasal delivery of raloxifene
10/14/1999WO1999051094A1 Intravaginal use of triclosan
10/14/1999WO1999045011A8 Glycine transport inhibitors
10/14/1999WO1999044628A8 Conjugates useful in the treatment of prostate cancer
10/14/1999WO1999044623A8 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid
10/14/1999WO1999043332A8 Antitumor combination comprising epirubicin and gemcitabine for the treatment of non-small-cell lung cancer
10/14/1999WO1999042089A3 Use of thiadiazolo[4,3-a]pyridine derivatives
10/14/1999WO1999042076A3 Compounds and methods for immunotherapy and diagnosis of tuberculosis
10/14/1999WO1999039702A3 Method for regulating size and growth of vascularized normal tissue
10/14/1999WO1999037604A3 Dialkyl ureas as calcitonin mimetics
10/14/1999WO1999036544A3 Neisseria meningitidis antigens
10/14/1999WO1999036090A9 Oral delivery of nucleic acid vaccines by particulate complexes
10/14/1999WO1999035157B1 Novel erythromycin derivatives
10/14/1999WO1999033840B1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha1-blocking action
10/14/1999WO1999027937A3 Method for inhibiting cytokine production by cells
10/14/1999WO1999026604A3 Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood
10/14/1999WO1999010486A3 Mdm2-specific antisense oligonucleotides
10/14/1999DE19913089A1 Composition comprising plant extracts from at least two of Bryonia, Ipecacuanha or Drosera, and antimony potassium tartrate, useful for treatment of chronic obstructive pulmonary disease, bronchitis, respiratory disorders and cancer
10/14/1999DE19901732A1 Herbal composition for tumor therapy
10/14/1999DE19816036A1 Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol
10/14/1999DE19815090A1 Kosmetische Mittel Cosmetic Products
10/14/1999DE19815060A1 Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie Pharmaceutical preparations for the therapy of side effects during and / or after a GnRHa therapy
10/14/1999DE19814838A1 Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung Indolyl-3-glyoxylic acid derivatives having anti-tumor activity
10/14/1999DE19814087A1 Feuchtigkeitsaktivierbares therapeutisches System Moisture-activatable therapeutic system
10/14/1999DE19814084A1 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's disease and process for its preparation
10/14/1999DE19814083A1 Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen A process for the production of transdermal therapeutic systems using basic alkali metal salts for the conversion of active substance salts into the free bases
10/14/1999DE19809243A1 Use of compounds with estrogen and gestagen activity for hormone replacement therapy
10/14/1999DE19807426A1 Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs A method for the treatment of diseases or disorders of the inner ear
10/14/1999CA2328607A1 Antidiabetic agents
10/14/1999CA2327706A1 Methods for inhibiting mrp1
10/14/1999CA2327670A1 Pulmonary and nasal delivery of raloxifene
10/14/1999CA2327617A1 Methods for inhibiting mrp1
10/14/1999CA2327513A1 N-aryloxyethyl-indoly-alkylamines for the treatment of depression
10/14/1999CA2327452A1 Methods for inhibiting mrp1
10/14/1999CA2327360A1 Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
10/14/1999CA2327359A1 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
10/14/1999CA2327303A1 N-aryloxyethylamine derivatives for the treatment of depression
10/14/1999CA2327290A1 Sulfonamide derivatives
10/14/1999CA2327279A1 Calcilytic compounds
10/14/1999CA2327188A1 Calcilytic compounds and method of use
10/14/1999CA2327185A1 Pyrazole inhibitors of cytokine production
10/14/1999CA2327113A1 Anti-inflammatory, antibacterial benzyl phenol agents
10/14/1999CA2327095A1 Compositions containing a combination of a creatine compound and a second agent
10/14/1999CA2327068A1 Maximizing effectiveness of substances used to improve health and well being
10/14/1999CA2326884A1 Thiazolo¬4,5-d|pyrimidines and pyridines as corticotropin releasing factor (crf) antagonists
10/14/1999CA2326759A1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
10/14/1999CA2326614A1 The use of polyamines in the treatment of dermatological symptoms
10/14/1999CA2326606A1 Aminoalkyl substituted 9h-pyridino¬2,3-b|indole and 9h-pyrimidino¬4,5-b|indole derivatives:crf1 and npy1 receptors
10/14/1999CA2326522A1 Pyrrolo¬1,2-a|pyrazine spla2 inhibitor
10/14/1999CA2326507A1 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin
10/14/1999CA2326497A1 Liposome composition and method for administering a quinolone
10/14/1999CA2326383A1 Aminoalkyl substituted pyrrolo¬2,3-b|pyridine and pyrrolo¬2,3-d|pyrimidine derivatives: modulators of crf1 receptors
10/14/1999CA2326319A1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino¬2,3-b|indole and 5,6,7,8-tetrahydro-9h-pyrimidino¬4,5-b|indole derivatives: crf1 specific ligands
10/14/1999CA2326185A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326184A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326143A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326140A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326139A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326130A1 Cationic lipid formulation delivering nucleic acid to peritoneal tumors
1 ... 6429 6430 6431 6432 6433 6434 6435 6436 6437 6438 6439 6440 6441 6442 6443 6444 6445 6446 6447 6448 6449 ... 7860